Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Ferrous sulfate anhydrous
Commonly known or available as Ferrous sulfate
Accession Number
DB13257  (DBSALT000084)
Type
Small Molecule
Groups
Approved
Description

Iron deficiency anemia is a large public health concern worldwide, especially in young children, infants, and women of childbearing age.4 This type of anemia occurs when iron intake, iron stores, and iron loss do not adequately support the formation of erythrocytes, also known as red blood cells.8

Ferrous sulfate is a synthetic agent used in the treatment of iron deficiency. It is the gold standard of oral iron therapy in the UK and many other countries.14,18

Structure
Thumb
Synonyms
  • iron sulfate (1:1)
  • iron(2+) sulfate (anhydrous)
  • iron(II) sulfate
Product Ingredients
IngredientUNIICASInChI Key
Ferrous sulfate39R4TAN1VT7782-63-0SURQXAFEQWPFPV-UHFFFAOYSA-L
Ferrous sulfate dihydrateG0Z544944910028-21-4KFJBRJOPXNCARV-UHFFFAOYSA-L
Ferrous sulfate monohydrateRIB00980VW17375-41-6XBDUTCVQJHJTQZ-UHFFFAOYSA-L
Ferrous sulfate sesquihydrate1OA214846O13463-43-9JJUUPAANEJLKEY-UHFFFAOYSA-J
Active Moieties
NameKindUNIICASInChI Key
IronunknownE1UOL152H77439-89-6XEEYBQQBJWHFJM-UHFFFAOYSA-N
Ferrous cationionicGW89581OWR15438-31-0CWYNVVGOOAEACU-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ferrous SulfateTablet65 mg/1OralHealthlife of Usa2017-12-05Not applicableUs
Ferrous SulfateTablet65 mg/1OralBoca Pharmacal, Inc.2010-09-142018-06-30Us
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ferinsol DropsSolution / dropsOralMead Johnson Nutritionals1951-12-311996-09-30Canada
Fero Grad FilmtabTablet, extended releaseOralAbbott1961-12-312008-06-06Canada
Ferrous SulfateTablet325 mg/1OralPreferreed Pharmaceuticals Inc.2004-06-18Not applicableUs68788 017920180907 15195 1hyuyyk
Ferrous SulfateTablet, film coated325 mg/1OralSun Pharmaceutical Industries Limited2014-07-01Not applicableUs
Ferrous SulfateTablet, film coated325 mg/1OralPhysicians Total Care, Inc.2005-07-222013-01-15Us
Ferrous SulfateTablet325 mg/1OralA-S Medication Solutions2001-02-19Not applicableUs
Ferrous SulfateTablet325 mg/1Oralbryant ranch prepack2001-02-19Not applicableUs
Ferrous SulfateTablet, film coated325 mg/1OralSun Pharmaceutical Industries Limited2014-07-01Not applicableUs
Ferrous SulfateTablet, film coated325 mg/1OralSpirit Pharmaceuticals, Llc2010-12-15Not applicableUs
Ferrous SulfateTablet, film coated325 mg/1OralRedPharm Drug, Inc.2018-01-01Not applicableUs
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Fero Grad 500Ferrous sulfate (105 mg) + Ascorbic acid (500 mg)Tablet, extended releaseOralAbbott1961-12-311999-08-09Canada
Ferrous SulfateFerrous sulfate (65 mg/1) + Calcium (20 mg/1)TabletOralMartin Ekwealor Pharmaceuticals, Inc.2014-09-01Not applicableUs
Formule No 204 Profil TabFerrous sulfate (9.5 mg) + Ascorbic acid (83.45 mg) + Potassium (35 mg)TabletOralPharmalab Inc.1987-12-312001-07-30Canada
Hemarexin TabFerrous sulfate (5 mg) + Ascorbic acid (75 mg) + Calcium (125 mg) + Copper (1 mg) + Cyanocobalamin (3 mcg) + Nicotinamide (25 mg) + Calcium pantothenate (5 mg) + Potassium Iodide (0.15 mg) + Pyridoxine hydrochloride (1 mg) + Riboflavin (5 mg) + Thiamine mononitrate (3 mg) + Vitamin A (10000 unit) + Vitamin D (400 unit)TabletOralLab Bio Chimique Inc.,Division Of Technilab Pharma Inc.1997-12-172004-08-03Canada
Hormodausse Plus Calc Et D TabFerrous sulfate (5 mg) + Calcium (500 mg) + Cholecalciferol (200 unit) + Cyanocobalamin (2.3 mcg) + Nicotinamide (6.86 mg) + Thiamine hydrochloride (2 mg)TabletOralLaboratoires Charton Laboratories1988-12-311999-01-16Canada
Iberet 500Ferrous sulfate (105 mg) + Ascorbic acid (500 mg) + Cyanocobalamin (0.025 mg) + Nicotinamide (30 mg) + Calcium pantothenate (10 mg) + Pyridoxine hydrochloride (5 mg) + Riboflavin (6 mg) + Thiamine mononitrate (6 mg)Tablet, extended releaseOralAbbott1965-12-312007-07-31Canada
K.L. Vitamin-mineralFerrous sulfate (6.3 mg) + Ascorbic acid (21 mg) + Biotin (105 mcg) + Calcium (250 mg) + Calcium Phosphate (150 mg) + Cholecalciferol (140 unit) + Chromium (42 mcg) + Copper (0.7 mg) + Cyanocobalamin (2.1 mcg) + Folic acid (0.140 mg) + Magnesium (80 mg) + Manganese (0.7 mg) + Nicotinamide (7 mg) + Calcium pantothenate (3.5 mg) + Potassium Iodide (0.0525 mg) + Pyridoxine hydrochloride (0.7 mg) + Riboflavin (0.6 mg) + Sodium selenate (24.5 mcg) + Sodium molybdate (25 mcg) + Thiamine (0.5 mg) + Vitamin A palmitate (1750 unit) + Zinc (5.25 mg) + alpha-Tocopherol acetate (10.5 unit)PowderOralAbundance Naturally LtdNot applicableNot applicableCanada
Kanga-kid Multi-vitamin & MineralFerrous sulfate (4 mg) + Ascorbic acid (50 mg) + Beta carotene (1600 unit) + Biotin (50 mcg) + Cyanocobalamin (2 mcg) + Riboflavin 5'-phosphate sodium anhydrous (1.6 mg) + Folic acid (0.1 mg) + Magnesium (50 mg) + Nicotinamide (15 mg) + Calcium pantothenate (5 mg) + Pyridoxine hydrochloride (1 mg) + Thiamine (1 mg) + alpha-Tocopherol acetate (10 unit)Tablet, effervescentOralLacombe Drugs (1992) LtdNot applicableNot applicableCanada
Kanga-kid Vitamins & IronFerrous sulfate (5 mg) + Cyanocobalamin (2.5 mcg) + Pyridoxine hydrochloride (5 mg) + Thiamine (10 mg)Tablet, effervescentOralLacombe Drugs (1992) LtdNot applicableNot applicableCanada
Kanga-V Multivitamins & MineralsFerrous sulfate (4 mg) + Ascorbic acid (100 mg) + Biotin (200 mcg) + Calcium (125 mg) + Chromium (20 mcg) + Copper (1 mg) + Cyanocobalamin (4 mcg) + Ergocalciferol (200 unit) + Folic acid (0.4 mg) + Magnesium (50 mg) + Manganese (0.5 mg) + Nicotinamide (40 mg) + Calcium pantothenate (8 mg) + Potassium Iodide (0.15 mg) + Pyridoxine hydrochloride (3 mg) + Riboflavin (10 mg) + Thiamine (9 mg) + Vitamin E (10 unit) + Zinc (2 mg)Tablet, effervescentOralLacombe Drugs (1992) LtdNot applicableNot applicableCanada
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Exact-Rx SODIUM SULFACETAMIDE and SULFER 10%/5% CleanserFerrous sulfate (50 mg/1g) + Sulfacetamide sodium (100 mg/1g)LotionTopicalExact Rx, Inc.2011-08-012017-04-20Us
Ferrous SulfateFerrous sulfate (325 mg/1)TabletOralA-S Medication Solutions2001-02-19Not applicableUs54569 454520180907 15195 5je2x2
Ferrous SulfateFerrous sulfate (65 mg/1) + Calcium (20 mg/1)TabletOralMartin Ekwealor Pharmaceuticals, Inc.2014-09-01Not applicableUs
Ferrous SulfateFerrous sulfate (325 mg/1)Tablet, film coatedOralCentral Texas Community Health Centers2014-07-01Not applicableUs
Ferrous SulfateFerrous sulfate (325 mg/1)TabletOralQualitest2001-02-192020-03-30Us0603 017920180913 8702 1u7d6nu
Ferrous SulfateFerrous sulfate (325 mg/1)TabletOralPreferreed Pharmaceuticals Inc.2004-06-18Not applicableUs68788 017920180907 15195 1hyuyyk
Ferrous SulfateFerrous sulfate (325 mg/1)TabletOralA-S Medication Solutions2001-02-19Not applicableUs54569 453720180907 15195 c2c2vz
Ferrous SulfateFerrous sulfate (325 mg/1)TabletOralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs53808 091820180907 15195 1xg3urs
Ferrous SulfateFerrous sulfate (325 mg/1)Tablet, film coatedOralRedPharm Drug, Inc.2018-01-01Not applicableUs
Ferrous SulfateFerrous sulfate monohydrate (325 mg/1)Tablet, film coatedOralSpirit Pharmaceuticals, Llc2010-12-15Not applicableUs
International/Other Brands
Anemifer / Aritoferon / Bioron / Blissferon / Caron / Dyaferon / Fe-Plus / Feklon / Feromin / Ferrifol / Ferrocebrina Solucion / Ferrogeme / Ferroglobin / Ferrograd / Ferrolin / Ferrosi / Ferrosi sulfas / Ferrous Sulfate Washington Pharm / Ferrous Sulfate-Minsheng Pharm / Fertonic / Fesyrup / Hierro Fabra / Hierro Richet / Hierro Vannier / Iberol / Inshel / Iron-200 / Jeferin / Kdiron / Kidiron / Pediafer Goutt / Pharmafer / Rhea Ferrous Sulfate / Sulfas Ferrosus / Sulfato Ferroso / Sulfato Ferroso Ecar / Sulfato Ferroso Kronos / Sulfato Ferroso L.Ch. / Sulfato Ferroso Richet / Sulfato Ferroso Sant Gall Friburg / Sulfato Ferroso Valma / TGI / Tibilin / United Home Fersulfate Iron / Valdefer / Vitafer-Fol
Categories
UNII
2IDP3X9OUD
CAS number
7720-78-7
Weight
Average: 151.908
Monoisotopic: 151.886671311
Chemical Formula
FeO4S
InChI Key
BAUYGSIQEAFULO-UHFFFAOYSA-L
InChI
InChI=1S/Fe.H2O4S/c;1-5(2,3)4/h;(H2,1,2,3,4)/q+2;/p-2
IUPAC Name
lambda2-iron(2+) sulfate
SMILES
[Fe++].[O-]S([O-])(=O)=O

Pharmacology

Indication

Ferrous sulfate is used for the prevention and treatment of iron deficiency anemia in adults and children.4,17,22

Associated Conditions
Pharmacodynamics

Ferrous sulfate replenishes iron, an essential component in hemoglobin, myoglobin, and various enzymes. It replaces the iron that is usually found in hemoglobin and myoglobin. Iron participates in oxygen transport and storage, electron transport and energy metabolism, antioxidant and beneficial pro-oxidant functions, oxygen sensing, tissue proliferation and growth, as well as DNA replication and repair.6,9

Mechanism of action

Iron is required to maintain optimal health, particularly for helping to form red blood cells (RBC) that carry oxygen around the body. A deficiency in iron indicates that the body cannot produce enough normal red blood cells.9,22 Iron deficiency anemia occurs when body stores of iron decrease to very low levels, and the stored iron is insufficient to support normal red blood cell (RBC) production. Insufficient dietary iron, impaired iron absorption, bleeding, pregnancy, or loss of iron through the urine can lead to iron deficiency.9,24 Symptoms of iron deficiency anemia include fatigue, breathlessness, palpitations, dizziness, and headache.

Taking iron in supplement form, such as ferrous sulfate, allows for more rapid increases in iron levels when dietary supply and stores are not sufficient.12 Iron is transported by the divalent metal transporter 1 (DMT1) across the endolysosomal membrane to enter the macrophage. It can then can be incorporated into ferritin and be stored in the macrophage or carried of the macrophage by ferroportin. This exported iron is oxidized by the enzyme to ceruloplasmin to Fe3+, followed by sequestration by transferrin for transport in the serum to various sites, including the bone marrow for hemoglobin synthesis or into the liver.6 Iron combines with porphyrin and globin chains to form hemoglobin, which is critical for oxygen delivery from the lungs to other tissues.19

TargetActionsOrganism
AHemoglobin subunit alpha
binder
Humans
ATransferrin receptor
substrate
Humans
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption

Approximately 5 – 10% of dietary iron is absorbed, and this absorption rate increases to up to 30% in iron deficiency states. Oral iron supplements are absorbed up to 60% via active and passive transport processes.17 Gastrointestinal absorption of iron occurs via strict regulation by the enterocyte and duodenal cytochrome and ferric reductase enzymes.6,24 The hormone hepcidin heavily regulates iron absorption and distribution throughout the body.22

The median time to maximum serum concentration (Tmax) is generally 4 hours after administration. Between 2-8 hours post administration, average serum iron concentrations fluctuate by 20%, according to one study.1 Bioavailability of iron depends on whether it is administered in a film coated tablet or enteric coated tablet. One pharmacokinetic study in healthy volunteers revealed a 30% bioavailability for enteric coated tablets. The AUC of enteric coated tablets varied between a lower limit of -46.93 to 5.25 µmolxh/l. Cmax is higher for film coated tablets, ranging from 3.4 to 22.1 µmol/h/l.10

It is advisable to take ferrous sulfate with ascorbic acid, as this practice may increase absorption.22,24 Avoid antacids, tea, coffee,tea, dairy products, eggs, and whole-grain bread for at least an hour after taking ferrous sulfate. Calcium can decrease iron absorption by 33% if taken concomitantly.17

Volume of distribution

About 60% of iron is distributed the erythrocytes.6 The remainder of the iron is found in muscle tissues (as a part of myoglobin), and in a variety of different enzymes, as well as in storage form. Most stored iron is in the form of ferritin, which can be found in the liver, bone marrow, spleen and, and muscle. Iron crosses the placenta and is also found in breast milk.17

Protein binding

The protein binding for ferrous sulfate is equal to or greater than 90%.17 It is bound to transferrin and ferritin, ferroportin, myoglobin, and other enzymes.22,24 Approximately 60% of iron is located in the erythrocytes as part of hemoglobin.6

Metabolism

The metabolism of iron is complex. Normally, iron exists in the ferrous (Fe2+) or ferric (Fe3+) state, but since Fe2+ is oxidized to Fe3+, which hydrolyzes to insoluble iron(III)hydroxides in neutral aqueous solutions, iron binds to plasma proteins and is either transported or stored throughout the body.6

There are three proteins that serve to regulate the storage and transport of ingested iron. The first protein , transferrin, transports iron in both the plasma and extracellular fluid. Ceruloplasmin in the plasma and hephaestin on the enterocyte participate in the oxidation and binding of iron to transferrin. The main role of transferrin is the chelation of iron to prevent the production of reactive oxygen species, while facilitating its transport into cells.24 The transferrin receptor, located on many cells that require iron, binds the transferrin complex and internalizes this complex. Ferritin is a protein that stores iron, making it readily available for body requirements.6

Route of elimination

Oral iron is recycled, with some loss in the urine, sweat, and desquamation. Some iron can be lost during menstrual bleeding9,17 This loss is balanced by changes in intestinal absorption. The enzyme hepcidin promotes the excretion of iron via the sloughing of enterocytes with ferritin stores into the feces.24

Half life

The half-life of orally administered iron is not readily available in the literature, with total effects lasting 2-4 months (congruent with the red blood cell life span)11 with an onset of action of 4 days and peak activity at 7-10 days.17

Clearance
Not Available
Toxicity

The toxicity of ferrous sulfate in humans depends on the amount of iron ingested. Up to 20 mg/kg of elemental iron is not toxic, 20-60 mg/kg has mild toxicity, and more than 60 mg/kg can lead to severe symptoms and morbidity.13

Overdose information

Iron containing products are the primary cause of drug overdose in children under 6 years of age.20 Iron is toxic to the gastrointestinal system, cardiovascular system, in addition to central nervous system. The most early reported effects following the excess ingestion of iron include nausea, flatulence, abdominal pain, diarrhea, constipation, and black/tarry stools.14 Symptoms of overdose in the later stages include bluish lips, fingernails, and palms, drowsiness, tachycardia, seizures, metabolic acidosis, hepatic injury, and cardiovascular dysfunction. Sequelae of iron sulfate overdose include intestinal obstruction, pyloric stenosis, and gastric scarring.17 If the patient is comatose or seizing, gastric lavage with sodium bicarbonate should be performed. Deferoxamine is the antidote for iron poisoning. Other supportive treatments to support fluid and electrolyte balance and correct metabolic acidosis are also advised.17 Hospitalization should continue for 24 h after the patient becomes asymptomatic to monitor for delayed onset of shock/gastrointestinal bleeding.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
3-Aza-2,3-Dihydrogeranyl DiphosphateFerrous sulfate anhydrous can cause a decrease in the absorption of 3-Aza-2,3-Dihydrogeranyl Diphosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Alendronic acidFerrous sulfate anhydrous can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
AlmasilateAlmasilate can cause a decrease in the absorption of Ferrous sulfate anhydrous resulting in a reduced serum concentration and potentially a decrease in efficacy.
AloglutamolAloglutamol can cause a decrease in the absorption of Ferrous sulfate anhydrous resulting in a reduced serum concentration and potentially a decrease in efficacy.
AluminiumAluminium can cause a decrease in the absorption of Ferrous sulfate anhydrous resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminium acetoacetateAluminium acetoacetate can cause a decrease in the absorption of Ferrous sulfate anhydrous resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminium glycinateAluminium glycinate can cause a decrease in the absorption of Ferrous sulfate anhydrous resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminium phosphateAluminium phosphate can cause a decrease in the absorption of Ferrous sulfate anhydrous resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Ferrous sulfate anhydrous resulting in a reduced serum concentration and potentially a decrease in efficacy.
AsenapineAsenapine can cause a decrease in the absorption of Ferrous sulfate anhydrous resulting in a reduced serum concentration and potentially a decrease in efficacy.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
  • Take with foods containing vitamin C. Foods rich in vitamin C increase the absorption of iron.

References

Synthesis Reference

Mitchell AG. The preparation and characterization of ferrous sulphate hydrates. (1984 Aug).J Pharm Pharmacol.

General References
  1. Leary A, Barthe L, Clavel T, Sanchez C, Oulmi-Castel M, Paillard B, Edmond JM, Brunner V: Pharmacokinetics of Ferrous Sulphate (Tardyferon(R)) after Single Oral Dose Administration in Women with Iron Deficiency Anaemia. Drug Res (Stuttg). 2016 Jan;66(1):51-6. doi: 10.1055/s-0035-1549934. Epub 2015 May 19. [PubMed:25989284]
  2. Conrad ME, Umbreit JN, Moore EG, Hainsworth LN, Porubcin M, Simovich MJ, Nakada MT, Dolan K, Garrick MD: Separate pathways for cellular uptake of ferric and ferrous iron. Am J Physiol Gastrointest Liver Physiol. 2000 Oct;279(4):G767-74. doi: 10.1152/ajpgi.2000.279.4.G767. [PubMed:11005764]
  3. Tolkien Z, Stecher L, Mander AP, Pereira DI, Powell JJ: Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis. PLoS One. 2015 Feb 20;10(2):e0117383. doi: 10.1371/journal.pone.0117383. eCollection 2015. [PubMed:25700159]
  4. Santiago P: Ferrous versus ferric oral iron formulations for the treatment of iron deficiency: a clinical overview. ScientificWorldJournal. 2012;2012:846824. doi: 10.1100/2012/846824. Epub 2012 May 2. [PubMed:22654638]
  5. Waldvogel-Abramowski S, Waeber G, Gassner C, Buser A, Frey BM, Favrat B, Tissot JD: Physiology of iron metabolism. Transfus Med Hemother. 2014 Jun;41(3):213-21. doi: 10.1159/000362888. Epub 2014 May 12. [PubMed:25053935]
  6. Geisser P, Burckhardt S: The pharmacokinetics and pharmacodynamics of iron preparations. Pharmaceutics. 2011 Jan 4;3(1):12-33. doi: 10.3390/pharmaceutics3010012. [PubMed:24310424]
  7. Cancado RD, Munoz M: Intravenous iron therapy: how far have we come? Rev Bras Hematol Hemoter. 2011;33(6):461-9. doi: 10.5581/1516-8484.20110123. [PubMed:23049364]
  8. Miller JL: Iron deficiency anemia: a common and curable disease. Cold Spring Harb Perspect Med. 2013 Jul 1;3(7). pii: cshperspect.a011866. doi: 10.1101/cshperspect.a011866. [PubMed:23613366]
  9. Abbaspour N, Hurrell R, Kelishadi R: Review on iron and its importance for human health. J Res Med Sci. 2014 Feb;19(2):164-74. [PubMed:24778671]
  10. Walker SE, Paton TW, Cowan DH, Manuel MA, Dranitsaris G: Bioavailability of iron in oral ferrous sulfate preparations in healthy volunteers. CMAJ. 1989 Sep 15;141(6):543-7. [PubMed:2776093]
  11. Kaestner L, Bogdanova A: Regulation of red cell life-span, erythropoiesis, senescence, and clearance. Front Physiol. 2014 Jul 18;5:269. doi: 10.3389/fphys.2014.00269. eCollection 2014. [PubMed:25101005]
  12. FERROUS SULFATE - National Library of Medicine HSDB Database - Toxnet [Link]
  13. Iron poisoning [Link]
  14. Ferrous Sulfate Supplementation Causes Significant Gastrointestinal Side-Effects in Adults: A Systematic Review and Meta-Analysis [Link]
  15. Ferrous sulfate, Daily Med [Link]
  16. Ferrous sulfate, epocrates [Link]
  17. Ferrous sulfate DavisPlus [Link]
  18. Ferrous Sulfate Tablet, Delayed Release (Enteric Coated) [Link]
  19. Antianemia Drugs [Link]
  20. Dailymed: Ferrous sulfate tablets [Link]
  21. The Science Company: Ferrous sulfate MSDS [Link]
  22. ODS Health Professional Fact Sheet: Iron [Link]
  23. Medicines UK: Ferrous sulfate 200mg oral tablets [Link]
  24. NIH Statpearls: Biochemistry, Iron Absorption [Link]
External Links
PubChem Compound
62662
PubChem Substance
347829289
ChemSpider
22804
ChEBI
75832
ChEMBL
CHEMBL1200830
Wikipedia
Iron(II)_sulfate
AHFS Codes
  • 20:04.04 — Iron Preparations
  • 88:29.00* — Minerals

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedOtherHealthy Volunteers1
1CompletedTreatmentIron Deficiency Anemia (IDA)1
1CompletedTreatmentIron Deficiency Anemia (IDA) / Subclinical Hypothyroidism1
1CompletedTreatmentIron-refractory, Iron-deficiency Anemia (IRIDA)1
2CompletedPreventionLead Toxicity1
2CompletedTreatmentAnemias1
2CompletedTreatmentAnemic, Critically Ill Patients1
2CompletedTreatmentAutism Spectrum Conditions/Disorders / Insomnia1
2CompletedTreatmentChronic Arsenic Poisoning1
2CompletedTreatmentIron Deficiency Anemia (IDA)1
2RecruitingTreatmentAnemias1
2RecruitingTreatmentIron Deficiency Anemia (IDA) / Restless Legs Syndrome (RLS)1
2RecruitingTreatmentIron-Deficiency Anemias1
2WithdrawnTreatmentInflammatory Bowel Diseases (IBD) / Iron Deficiency Anemia (IDA)1
2, 3CompletedTreatmentHeart Failure, Systolic / Iron-Deficiency Anemias1
2, 3CompletedTreatmentIron Deficiency Anemia (IDA)1
2, 3TerminatedTreatmentIron-Deficiency Anemias / Postpartum Depression / Puerperal Disorders1
2, 3Unknown StatusTreatmentAnemias / Heart Failure1
3Active Not RecruitingTreatmentIron-Deficiency Anemias1
3CompletedOtherAnemias1
3CompletedPreventionAnemias / Iron Deficiency1
3CompletedPreventionIron Deficiency1
3CompletedTreatmentAnemias6
3CompletedTreatmentChronic Kidney Disease (CKD) / Iron Deficiency Anemia (IDA)1
3CompletedTreatmentHip Fracture1
3CompletedTreatmentIron Deficiency Anemia (IDA)1
3CompletedTreatmentPostpartum Anemia1
3Not Yet RecruitingTreatmentIron Deficiency Anemia (IDA)1
3Not Yet RecruitingTreatmentIron Deficiency Anemia (IDA) / Pregnancy Related1
3RecruitingTreatmentAnemias / Iron Deficiency Anemia (IDA)1
3RecruitingTreatmentIron Deficiency Anemia (IDA)3
3RecruitingTreatmentIron-Deficiency / Postpartum Anemia Nos1
4Active Not RecruitingTreatmentIron Deficiency Anemia (IDA) Secondary to Inflammatory Bowel Disease (IBD) or Gastric Bypass1
4Active Not RecruitingTreatmentLeiomyomas1
4CompletedTreatmentAnemias1
4CompletedTreatmentAnemias / Neoplasms, Colorectal1
4CompletedTreatmentChronic Renal Failure (CRF) / Iron-Deficiency Anemias2
4CompletedTreatmentCrohn's Disease (CD) / Ulcerative Colitis1
4CompletedTreatmentFatigue / Iron Deficiency1
4CompletedTreatmentHyperemesis Gravidarum / Morning Sickness / Nausea / Pregnancy / Vomiting1
4CompletedTreatmentIron Deficiency Anemia (IDA)1
4CompletedTreatmentIron Deficiency Anemia Treatment1
4CompletedTreatmentIron Deficiency / Iron Deficiency Anemia (IDA) / Pregnancy1
4Enrolling by InvitationTreatmentPost Gastrectomy Anemia1
4Not Yet RecruitingTreatmentAnemia of Pregnancy / Iron Deficiency Anemia (IDA) / Pregnancy Related1
4Not Yet RecruitingTreatmentHeavy Menstrual Bleeding / Iron Deficiency Anemia (IDA)1
4RecruitingPreventionAnemias / Iron-Deficiency1
4RecruitingTreatmentAnemia During Pregnancy1
4RecruitingTreatmentChronic Kidney Disease (CKD) / Kidney Insufficiency, Chronic1
4RecruitingTreatmentIron Deficiency Anemia (IDA)1
4RecruitingTreatmentIron Deficiency Anemia of Pregnancy / Iron Malabsorption1
4TerminatedTreatmentChronic Kidney Disease (CKD) / Iron-Deficiency Anemias1
4Unknown StatusTreatmentAnemias1
4WithdrawnTreatmentIron Deficiency1
Not AvailableCompletedNot AvailableAnemias1
Not AvailableCompletedBasic ScienceIron Bioavailability1
Not AvailableCompletedOtherAllogenic Transfusion / Hip Arthroplasty / Knee Replacement Surgery / Perioperative Anaemia1
Not AvailableCompletedPreventionAnaemia in Children1
Not AvailableCompletedPreventionAnemia of Prematurity / Iron Deficiency1
Not AvailableCompletedPreventionAnemia of Prematurity / Iron Deficiency / Neurodevelopmental Delay1
Not AvailableCompletedPreventionPostpartum Anemia1
Not AvailableCompletedTreatmentAnemias / Chronic Kidney Disease (CKD) / Iron Deficiency1
Not AvailableCompletedTreatmentAnemias / Helminthiases / Schistosoma infection1
Not AvailableCompletedTreatmentCystic Fibrosis (CF) / Iron-Deficiency Anemias1
Not AvailableCompletedTreatmentEPP / Protoporphyria, Erythropoietic / X-Linked Protoporphyria / XLP1
Not AvailableRecruitingTreatmentAnemia in Pregnancy1
Not AvailableSuspendedPreventionLatent Iron Deficiency1
Not AvailableTerminatedTreatmentHereditary Haemorrhagic Telangiectasia (HHT)1
Not AvailableUnknown StatusPreventionExcessive Amount of Blood / Fluid Transfusion1
Not AvailableUnknown StatusTreatmentHealthy Volunteers1
Not AvailableWithdrawnPreventionAnemias1
Not AvailableWithdrawnTreatmentIDA in the Post-bariatric Surgical Patient1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
LotionTopical
Solution / dropsOral
Tablet, extended releaseOral
Tablet, extended releaseOral
ElixirOral220 mg/5mL
TabletOral
TabletOral324 mg/1
TabletOral325 mg/1
TabletOral65 mg/1
Tablet, coatedOral325 mg/1
Tablet, film coatedOral325 mg/1
Tablet, film coatedOral65 mg/1
Tablet, coatedOral65 mg/1
Capsule, extended releaseOral
PowderOral
Tablet, effervescentOral
Liquid; tabletOral
LiquidOral
SolutionOral
CapsuleOral
Tablet, delayed releaseOral
TabletOral
Tablet, film coatedOral
Solution / dropsOral
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)64https://www.chemicalbook.com/ProductChemicalPropertiesCB9232125_EN.htm
boiling point (°C)> 300 °CMSDS
water solubility25.6 g/100 mLhttps://www.chemicalbook.com/ProductChemicalPropertiesCB9232125_EN.htm
logP-0.84http://foodb.ca/compounds/FDB014740
pKa-3http://foodb.ca/compounds/FDB014740
Predicted Properties
PropertyValueSource
logP-0.84ChemAxon
pKa (Strongest Acidic)-3ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area80.26 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity11.53 m3·mol-1ChemAxon
Polarizability5.81 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of inorganic compounds known as transition metal sulfates. These are inorganic compounds in which the largest oxoanion is sulfate, and in which the heaviest atom not in an oxoanion is a transition metal.
Kingdom
Inorganic compounds
Super Class
Mixed metal/non-metal compounds
Class
Transition metal oxoanionic compounds
Sub Class
Transition metal sulfates
Direct Parent
Transition metal sulfates
Alternative Parents
Inorganic salts / Inorganic oxides
Substituents
Transition metal sulfate / Inorganic oxide / Inorganic salt
Molecular Framework
Not Available
External Descriptors
metal sulfate, iron molecular entity (CHEBI:75832)

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Binder
General Function
Oxygen transporter activity
Specific Function
Involved in oxygen transport from the lung to the various peripheral tissues.
Gene Name
HBA1
Uniprot ID
P69905
Uniprot Name
Hemoglobin subunit alpha
Molecular Weight
15257.405 Da
References
  1. Geisser P, Burckhardt S: The pharmacokinetics and pharmacodynamics of iron preparations. Pharmaceutics. 2011 Jan 4;3(1):12-33. doi: 10.3390/pharmaceutics3010012. [PubMed:24310424]
  2. Johnson-Wimbley TD, Graham DY: Diagnosis and management of iron deficiency anemia in the 21st century. Therap Adv Gastroenterol. 2011 May;4(3):177-84. doi: 10.1177/1756283X11398736. [PubMed:21694802]
  3. Alleyne M, Horne MK, Miller JL: Individualized treatment for iron-deficiency anemia in adults. Am J Med. 2008 Nov;121(11):943-8. doi: 10.1016/j.amjmed.2008.07.012. [PubMed:18954837]
Kind
Protein group
Organism
Humans
Pharmacological action
Yes
Actions
Substrate
General Function
Virus receptor activity
Specific Function
Cellular uptake of iron occurs via receptor-mediated endocytosis of ligand-occupied transferrin receptor into specialized endosomes. Endosomal acidification leads to iron release. The apotransferri...

Components:
References
  1. Geisser P, Burckhardt S: The pharmacokinetics and pharmacodynamics of iron preparations. Pharmaceutics. 2011 Jan 4;3(1):12-33. doi: 10.3390/pharmaceutics3010012. [PubMed:24310424]
  2. Johnson-Wimbley TD, Graham DY: Diagnosis and management of iron deficiency anemia in the 21st century. Therap Adv Gastroenterol. 2011 May;4(3):177-84. doi: 10.1177/1756283X11398736. [PubMed:21694802]
  3. Alleyne M, Horne MK, Miller JL: Individualized treatment for iron-deficiency anemia in adults. Am J Med. 2008 Nov;121(11):943-8. doi: 10.1016/j.amjmed.2008.07.012. [PubMed:18954837]

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Substrate
General Function
Ferroxidase activity
Specific Function
Ceruloplasmin is a blue, copper-binding (6-7 atoms per molecule) glycoprotein. It has ferroxidase activity oxidizing Fe(2+) to Fe(3+) without releasing radical oxygen species. It is involved in iro...
Gene Name
CP
Uniprot ID
P00450
Uniprot Name
Ceruloplasmin
Molecular Weight
122204.45 Da
References
  1. Sozmen EY, Kavakli K, Cetinkaya B, Akcay YD, Yilmaz D, Aydinok Y: Effects of iron(II) salts and iron(III) complexes on trace element status in children with iron-deficiency anemia. Biol Trace Elem Res. 2003 Jul;94(1):79-86. doi: 10.1385/BTER:94:1:79. [PubMed:12907830]
  2. Frieden E, Hsieh HS: Ceruloplasmin: the copper transport protein with essential oxidase activity. Adv Enzymol Relat Areas Mol Biol. 1976;44:187-236. doi: 10.1002/9780470122891.ch6. [PubMed:775938]
  3. The Pharmacokinetics and Pharmacodynamics of Iron Preparations [Link]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Liver-produced hormone that constitutes the main circulating regulator of iron absorption and distribution across tissues. Acts by promoting endocytosis and degradation of ferroportin, leading to the retention of iron in iron-exporting cells and decreased flow of iron into plasma. Controls the major flows of iron into plasma: absorption of dietary iron in the intestine, recycling of iron by macrophages, which phagocytose old erythrocytes and other cells, and mobilization of stored iron from hepatocytes (PubMed:22306005).
Specific Function
Hormone activity
Gene Name
HAMP
Uniprot ID
P81172
Uniprot Name
Hepcidin
Molecular Weight
9408.075 Da
References
  1. Zimmermann MB, Troesch B, Biebinger R, Egli I, Zeder C, Hurrell RF: Plasma hepcidin is a modest predictor of dietary iron bioavailability in humans, whereas oral iron loading, measured by stable-isotope appearance curves, increases plasma hepcidin. Am J Clin Nutr. 2009 Nov;90(5):1280-7. doi: 10.3945/ajcn.2009.28129. Epub 2009 Sep 9. [PubMed:19740974]
  2. Hwang SI, Lee YY, Park JO, Norton HJ, Clemens E, Schrum LW, Bonkovsky HL: Effects of a single dose of oral iron on hepcidin concentrations in human urine and serum analyzed by a robust LC-MS/MS method. Clin Chim Acta. 2011 Nov 20;412(23-24):2241-7. doi: 10.1016/j.cca.2011.08.014. Epub 2011 Aug 16. [PubMed:21867695]
  3. NIH Statpearls: Biochemistry, Iron Absorption [Link]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Transferrin receptor binding
Specific Function
Transferrins are iron binding transport proteins which can bind two Fe(3+) ions in association with the binding of an anion, usually bicarbonate. It is responsible for the transport of iron from si...
Gene Name
TF
Uniprot ID
P02787
Uniprot Name
Serotransferrin
Molecular Weight
77063.195 Da
References
  1. Geisser P, Burckhardt S: The pharmacokinetics and pharmacodynamics of iron preparations. Pharmaceutics. 2011 Jan 4;3(1):12-33. doi: 10.3390/pharmaceutics3010012. [PubMed:24310424]
  2. Abbaspour N, Hurrell R, Kelishadi R: Review on iron and its importance for human health. J Res Med Sci. 2014 Feb;19(2):164-74. [PubMed:24778671]
  3. NIH Statpearls: Biochemistry, Iron Absorption [Link]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Ferroxidase activity
Specific Function
May function as a ferroxidase for ferrous (II) to ferric ion (III) conversion and may be involved in copper transport and homeostasis. Implicated in iron homeostasis and may mediate iron efflux ass...
Gene Name
HEPH
Uniprot ID
Q9BQS7
Uniprot Name
Hephaestin
Molecular Weight
130447.755 Da
References
  1. Anderson GJ, Frazer DM: Current understanding of iron homeostasis. Am J Clin Nutr. 2017 Dec;106(Suppl 6):1559S-1566S. doi: 10.3945/ajcn.117.155804. Epub 2017 Oct 25. [PubMed:29070551]
  2. Lonnerdal B: Calcium and iron absorption--mechanisms and public health relevance. Int J Vitam Nutr Res. 2010 Oct;80(4-5):293-9. doi: 10.1024/0300-9831/a000036. [PubMed:21462112]
  3. NIH Statpearls: Biochemistry, Iron Absorption [Link]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Ferric-chelate reductase that reduces Fe(3+) to Fe(2+). Present at the brush border of duodenal enterocytes where it probably reduces dietary Fe(3+) thereby facilitating its transport into the mucosal cells. Uses ascorbate as electron donor. May be involved in extracellular ascorbate recycling in erythrocyte membranes. May also act as a ferrireductase in airway epithelial cells.
Specific Function
Ferric-chelate reductase activity
Gene Name
CYBRD1
Uniprot ID
Q53TN4
Uniprot Name
Cytochrome b reductase 1
Molecular Weight
31641.005 Da
References
  1. Geisser P, Burckhardt S: The pharmacokinetics and pharmacodynamics of iron preparations. Pharmaceutics. 2011 Jan 4;3(1):12-33. doi: 10.3390/pharmaceutics3010012. [PubMed:24310424]
  2. NIH Statpearls: Biochemistry, Iron Absorption [Link]

Transporters

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Zinc ion transmembrane transporter activity
Specific Function
Important in metal transport, in particular iron. Can also transport manganese, cobalt, cadmium, nickel, vanadium and lead. Involved in apical iron uptake into duodenal enterocytes. Involved in iro...
Gene Name
SLC11A2
Uniprot ID
P49281
Uniprot Name
Natural resistance-associated macrophage protein 2
Molecular Weight
62265.195 Da
References
  1. Geisser P, Burckhardt S: The pharmacokinetics and pharmacodynamics of iron preparations. Pharmaceutics. 2011 Jan 4;3(1):12-33. doi: 10.3390/pharmaceutics3010012. [PubMed:24310424]
  2. Wolff NA, Garrick MD, Zhao L, Garrick LM, Ghio AJ, Thevenod F: A role for divalent metal transporter (DMT1) in mitochondrial uptake of iron and manganese. Sci Rep. 2018 Jan 9;8(1):211. doi: 10.1038/s41598-017-18584-4. [PubMed:29317744]
  3. Zoller H, Koch RO, Theurl I, Obrist P, Pietrangelo A, Montosi G, Haile DJ, Vogel W, Weiss G: Expression of the duodenal iron transporters divalent-metal transporter 1 and ferroportin 1 in iron deficiency and iron overload. Gastroenterology. 2001 May;120(6):1412-9. doi: 10.1053/gast.2001.24033. [PubMed:11313311]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
May be involved in iron export from duodenal epithelial cell and also in transfer of iron between maternal and fetal circulation. Mediates iron efflux in the presence of a ferroxidase (hephaestin and/or ceruloplasmin).
Specific Function
Ferrous iron transmembrane transporter activity
Gene Name
SLC40A1
Uniprot ID
Q9NP59
Uniprot Name
Solute carrier family 40 member 1
Molecular Weight
62541.55 Da
References
  1. Zoller H, Koch RO, Theurl I, Obrist P, Pietrangelo A, Montosi G, Haile DJ, Vogel W, Weiss G: Expression of the duodenal iron transporters divalent-metal transporter 1 and ferroportin 1 in iron deficiency and iron overload. Gastroenterology. 2001 May;120(6):1412-9. doi: 10.1053/gast.2001.24033. [PubMed:11313311]
  2. Abbaspour N, Hurrell R, Kelishadi R: Review on iron and its importance for human health. J Res Med Sci. 2014 Feb;19(2):164-74. [PubMed:24778671]
  3. NIH Statpearls: Biochemistry, Iron Absorption [Link]

Drug created on June 23, 2017 14:38 / Updated on February 27, 2020 21:29